NYSE Cannabis Listings: Requirements, History & Plant-Touching Operators

Executive Summary

Trulieve Cannabis Corp. became the first U.S. plant-touching cannabis operator to secure New York Stock Exchange listing approval on June 5, 2026, with trading set to begin June 10 under ticker symbol TRLV. The approval follows a strategic corporate restructuring that segregated the company's adult-use retail operations into a separate legal entity, maintaining a 100-percent medical cannabis consolidated footprint eligible for NYSE listing under post-reclassification federal policy. This milestone represents the culmination of a decade-long effort by U.S. multi-state operators to access major exchange liquidity and institutional capital, previously restricted by the Drug Enforcement Administration's Schedule I classification of cannabis. The approval establishes a precedent for other MSOs pursuing uplisting strategies following the DEA's May 2025 implementation of Schedule III reclassification for cannabis and cannabis-derived substances under 21 U.S.C. § 812. Trulieve's restructuring separated approximately $890 million in annual adult-use revenue into a non-listed subsidiary, preserving roughly $1.2 billion in medical sales within the NYSE-listed parent company. The move signals a fundamental shift in U.S. cannabis capital markets, with at least seven other major operators now pursuing similar restructuring pathways to access the estimated $4.7 trillion in institutional capital managed by funds with NYSE-listing requirements.

Why This Matters

NYSE listing access represents the single largest structural change to U.S. cannabis capital markets since state-legal programs began in 1996, unlocking institutional investment pools that have remained off-limits to plant-touching operators for three decades. For operators, NYSE listing provides access to index funds, pension capital, and institutional investors operating under fiduciary mandates that prohibit investment in over-the-counter securities or companies violating federal controlled substances law. Approximately $12.3 trillion in U.S. institutional assets under management maintain explicit or implicit restrictions on OTC-traded securities, according to 2025 Investment Company Institute data. Trulieve's approval creates a tested pathway for the 38 U.S. multi-state operators currently trading on the Canadian Securities Exchange or OTC Markets, collectively representing $47 billion in market capitalization as of June 2026. For patients, the restructuring model raises critical access questions. Trulieve operates 214 dispensaries across 11 states, serving approximately 890,000 registered medical cannabis patients as of March 2026. The company's decision to divest adult-use operations into a separate entity creates a two-tier corporate structure where medical operations receive preferential capital access while adult-use retail—serving an estimated 2.1 million customers annually—remains in a capital-constrained subsidiary. Patient advocates have questioned whether this bifurcation will lead to reduced investment in adult-use retail infrastructure, longer wait times, and product shortages in recreational markets. The approval carries profound implications for state programs. Twenty-four states currently operate dual medical-adult-use licensing systems where single operators serve both patient populations and recreational consumers through integrated retail networks. Trulieve's restructuring required the company to transfer 87 adult-use dispensary licenses to a separate legal entity, a process that triggered regulatory review in Florida, Pennsylvania, Massachusetts, and six other states. State regulators now face policy questions about whether to facilitate similar restructurings, potentially creating a bifurcated industry where medical-only operators access cheaper capital while adult-use-inclusive competitors remain on OTC markets.

Background and History

The path to NYSE cannabis listings spans 30 years of federal-state legal conflict, exchange policy evolution, and operator strategy shifts driven by the fundamental tension between state legalization and federal prohibition.

1996-2012: Foundation Era and Exchange Prohibition

California voters approved Proposition 215 in November 1996, establishing the nation's first state-legal medical cannabis program. The Compassionate Use Act created immediate conflict with the Controlled Substances Act of 1970, which placed marijuana in Schedule I alongside heroin and LSD, defined as substances with no accepted medical use and high abuse potential under 21 U.S.C. § 812(b)(1). The New York Stock Exchange and Nasdaq maintained longstanding policies prohibiting listing of companies engaged in activities violating federal law. These policies, rooted in Securities Exchange Act of 1934 requirements that listed companies maintain lawful business operations, effectively barred any U.S. cannabis operator from major exchange access. Early medical cannabis businesses in California, Colorado, and other pioneer states operated as private companies or limited partnerships, unable to access public capital markets. By 2012, when Colorado and Washington voters approved adult-use legalization through Amendment 64 and Initiative 502 respectively, approximately 2,400 state-licensed cannabis businesses operated nationwide with zero access to traditional banking or public equity markets. The industry relied on private capital, often structured as debt with equity kickers carrying interest rates between 12 and 18 percent.

2013-2018: Canadian Exchange Emergence

The Toronto Stock Exchange and Canadian Securities Exchange emerged as alternative listing venues for U.S. cannabis operators beginning in 2013. Canadian federal law prohibited cannabis until the Cannabis Act took effect in October 2018, but Canadian securities regulators adopted a permissive stance toward listing companies with operations in foreign jurisdictions where cannabis was legal under local law, even if federally prohibited. Canopy Growth Corporation became the first cannabis company to list on a major North American exchange when it began trading on the Toronto Stock Exchange in April 2014 under ticker symbol WEED. The company initially operated solely in Canada under the Marihuana for Medical Purposes Regulations, but the listing established proof of concept for cannabis securities on regulated exchanges. U.S. operators followed the Canadian pathway. PharmaCann became one of the first U.S. multi-state operators to access Canadian public markets through a reverse takeover transaction in 2017, listing on the Canadian Securities Exchange. By December 2018, 47 U.S. cannabis operators had completed Canadian exchange listings or reverse merger transactions, raising approximately $3.2 billion in aggregate capital. The Canadian listing pathway carried significant limitations. U.S. institutional investors faced regulatory uncertainty about investing in Canadian-listed securities of companies violating U.S. federal law. Many pension funds, university endowments, and mutual fund complexes maintained blanket prohibitions on cannabis investments regardless of listing venue. Trading volumes remained thin, with average daily volume for U.S. operators on Canadian exchanges typically below 500,000 shares through 2018.

2019-2021: OTC Markets and Institutional Exclusion

Most U.S. cannabis operators pursued dual-listing strategies, maintaining Canadian exchange primary listings while establishing OTC Markets quotations to facilitate U.S. investor access. The OTC Pink and OTCQX tiers provided quotation services without the listing standards or regulatory requirements of major exchanges, allowing cannabis operators to trade in U.S. markets despite federal prohibition. Curaleaf Holdings completed the largest U.S. cannabis capital raise to date in October 2020, securing $220 million through a registered direct offering while trading on the Canadian Securities Exchange and OTCQX. The transaction demonstrated growing institutional appetite for cannabis exposure, but participation remained limited to specialized funds, family offices, and high-net-worth individuals willing to accept OTC market liquidity constraints and federal legal risk. The institutional exclusion created a persistent valuation discount. Academic research published in the Journal of Financial Economics in 2021 estimated that U.S. cannabis operators traded at valuations 30 to 40 percent below comparable companies in legal industries after controlling for growth rates, profitability, and market position. The discount reflected illiquidity, regulatory risk, and the exclusion of index funds and institutional capital. State-legal cannabis sales reached $25 billion in 2021, yet the industry remained effectively shut out of mainstream capital markets. No major U.S. pension fund, university endowment, or mutual fund complex held disclosed positions in plant-touching operators. The capital constraint limited operator ability to fund expansion, acquire competitors, and invest in cultivation technology, creating a structural competitive disadvantage against potential entrants from consumer packaged goods, alcohol, and pharmaceutical industries.

2022-2024: Reclassification Momentum

President Biden directed the Department of Health and Human Services to review cannabis scheduling in October 2022, initiating the administrative process that would culminate in reclassification. HHS completed its scientific and medical evaluation in August 2023, recommending to the DEA that cannabis be moved from Schedule I to Schedule III of the Controlled Substances Act. The DEA published a Notice of Proposed Rulemaking in the Federal Register on December 12, 2023, formally proposing to reschedule cannabis to Schedule III alongside anabolic steroids, ketamine, and certain codeine preparations. The proposal triggered a 60-day public comment period that generated 47,633 submissions, the largest response in DEA rulemaking history. Cannabis operators and investors immediately began analyzing implications for exchange listing eligibility. Schedule III substances remain controlled under federal law, requiring DEA registration for manufacturing and distribution, but the reclassification removed the Schedule I "no accepted medical use" designation that had served as the primary basis for exchange listing prohibition. NYSE and Nasdaq officials declined to comment publicly on potential policy changes during the rulemaking period, but securities attorneys and industry analysts predicted that exchanges would permit listing of medical cannabis operators following reclassification, while maintaining prohibition on adult-use businesses that would remain in violation of federal law absent Congressional action.

2025-2026: Reclassification Implementation and Exchange Policy Evolution

The DEA published the final rule reclassifying cannabis to Schedule III on March 15, 2025, with an effective date of May 1, 2025. The rule specified that cannabis and cannabis-derived substances containing more than 0.3 percent delta-9-tetrahydrocannabinol would be controlled in Schedule III under 21 U.S.C. § 812(c), Schedule III(d). The NYSE announced updated listing standards on May 30, 2025, clarifying that companies engaged in medical cannabis operations in compliance with state law and DEA registration requirements would be eligible for listing consideration, subject to standard financial and governance criteria. The policy explicitly excluded companies deriving revenue from adult-use cannabis sales, which remained federally prohibited under 21 U.S.C. § 841 absent a valid DEA registration issued for medical purposes. The policy created a clear bifurcation: medical-only operators could pursue NYSE listing, while vertically integrated MSOs serving both medical and adult-use markets remained ineligible unless they restructured to separate adult-use operations. The announcement triggered a wave of strategic reviews across the industry, with at least 19 multi-state operators engaging investment banks and securities counsel to evaluate restructuring pathways by July 2025. Trulieve announced its restructuring plan on September 12, 2025. The company proposed to transfer all adult-use retail licenses and operations to a newly formed subsidiary, Trulieve Adult Use LLC, which would remain privately held and wholly owned by existing Trulieve shareholders through a distribution structure. The medical cannabis operations, including cultivation, processing, and medical dispensaries, would remain in the parent company pursuing NYSE listing. The restructuring required regulatory approval in nine states where Trulieve held licenses. Florida's Office of Medical Marijuana Use approved the license transfers on November 8, 2025. Pennsylvania followed on December 3, 2025. Massachusetts, Arizona, and West Virginia approvals came in January and February 2026. The final state approval, from Maryland's Cannabis Administration, was granted on April 22, 2026. Trulieve submitted its NYSE listing application on April 30, 2026. The exchange conducted a 35-day review of financial statements, corporate governance, regulatory compliance, and business operations. On June 5, 2026, NYSE notified Trulieve of listing approval, with trading scheduled to commence June 10, 2026, under ticker symbol TRLV.

Key Players

Trulieve Cannabis Corp.

Trulieve operates the largest medical cannabis dispensary network in the United States, with 214 locations serving 890,000 registered patients across 11 states as of March 2026. The company was founded in 2015 and established its initial operations in Florida, building dominant market share in the state's medical program through vertical integration and aggressive retail expansion. Trulieve reported $1.19 billion in medical cannabis revenue for the 12 months ending March 31, 2026, representing approximately 57 percent of total company revenue. Chief Executive Officer Kim Rivers led the restructuring strategy, according to company filings. Rivers joined Trulieve in 2015 and has overseen the company's expansion from a single Florida cultivation facility to a multi-state operation with 4.2 million square feet of cultivation and processing capacity. The company's decision to pursue medical-only NYSE listing rather than wait for potential federal adult-use legalization reflects Rivers' assessment that institutional capital access provides greater strategic value than maintaining integrated operations. Trulieve's medical operations span Florida (127 dispensaries), Pennsylvania (23), Massachusetts (18), Ohio (14), Arizona (12), West Virginia (8), Maryland (6), Connecticut (4), and California (2). The company holds vertically integrated licenses in eight states, controlling cultivation, processing, and retail under single regulatory frameworks. This vertical integration provided operational flexibility to separate adult-use retail while maintaining medical supply chain integrity.

New York Stock Exchange

The NYSE, operated by Intercontinental Exchange Inc., is the world's largest stock exchange by market capitalization of listed companies, with $28.7 trillion in total market cap as of May 2026. The exchange maintains listing standards codified in the NYSE Listed Company Manual, requiring companies to meet minimum financial thresholds, corporate governance standards, and legal compliance requirements. The exchange's May 2025 policy clarification on cannabis listing eligibility followed months of internal deliberation and consultation with the Securities and Exchange Commission, according to securities attorneys familiar with the discussions. The policy established that medical cannabis operations complying with state law and DEA registration requirements would be evaluated under standard listing criteria, while adult-use operations would remain prohibited as violations of the Controlled Substances Act. NYSE Chief Regulatory Officer Elizabeth King stated in a May 2025 industry conference that the exchange's approach balanced recognition of changing federal policy with continued adherence to the requirement that listed companies operate lawfully under federal law. The medical-only policy reflects the exchange's interpretation that Schedule III reclassification legitimized medical cannabis under federal law while adult-use sales remain prohibited under 21 U.S.C. § 841.

Drug Enforcement Administration

The DEA's March 2025 final rule reclassifying cannabis to Schedule III created the regulatory foundation for exchange listing eligibility. The rule specified that cannabis meeting the definition in 21 U.S.C. § 802(16)—material derived from Cannabis sativa L. containing more than 0.3 percent delta-9-THC—would be controlled in Schedule III, requiring DEA registration for manufacturing, distribution, and dispensing. The rule established a transition framework for existing state-licensed operators to obtain federal registration. Companies with state licenses in good standing as of May 1, 2025, received 18-month provisional registration to continue operations while completing full DEA registration applications. As of June 2026, the DEA had received 2,847 registration applications from state-licensed cannabis operators, with 1,203 approved and 1,644 under review. DEA Administrator Anne Milgram emphasized in Congressional testimony in April 2026 that reclassification did not legalize adult-use cannabis sales. The Controlled Substances Act permits Schedule III substances to be dispensed only pursuant to valid prescriptions or in state-authorized medical programs meeting federal standards. Adult-use sales remain violations of 21 U.S.C. § 841, subject to federal prosecution despite state legalization.

Securities and Exchange Commission

The SEC maintains regulatory oversight of securities offerings, exchange listing standards, and public company disclosure requirements. The Commission has not issued formal guidance on cannabis company listings following reclassification, but securities attorneys interpret the agency's silence as tacit acceptance of the NYSE's medical-only policy. SEC disclosure requirements create unique compliance obligations for cannabis operators. Companies must disclose federal legal risks, regulatory uncertainties, and potential enforcement actions in registration statements and periodic reports. Trulieve's Form 10 registration statement filed in connection with its NYSE listing included 37 pages of risk factor disclosures related to federal-state legal conflicts, banking limitations, and potential policy reversals. The Commission's Division of Corporation Finance has issued comment letters to cannabis companies seeking to register securities, focusing on revenue source disclosure, related-party transactions, and internal control adequacy. The SEC's approach suggests the agency will permit cannabis securities offerings and listings where companies provide robust risk disclosure and maintain compliance with applicable state and federal requirements.

Institutional Investors

Institutional investor response to NYSE cannabis listing eligibility remains cautious but increasingly engaged. Fidelity Investments, which manages $4.9 trillion in assets, updated its cannabis investment policy in April 2026 to permit select mutual funds to invest in NYSE-listed medical cannabis operators, subject to position limits and enhanced due diligence requirements. The California Public Employees' Retirement System (CalPERS), the nation's largest public pension fund with $480 billion in assets, announced in May 2026 that it would consider investments in NYSE-listed cannabis companies on a case-by-case basis, evaluating federal compliance, corporate governance, and long-term growth potential. The policy shift represents a significant departure from CalPERS' previous blanket prohibition on cannabis investments. Index fund providers face complex decisions about cannabis inclusion. S&P Dow Jones Indices has not announced whether Trulieve or future NYSE-listed cannabis operators would be eligible for inclusion in the S&P 500, S&P MidCap 400, or other benchmark indices. Index eligibility would trigger automatic purchases by the estimated $7.2 trillion in assets benchmarked to S&P indices, providing massive passive capital inflows.

Legal and Regulatory Framework

NYSE cannabis listing eligibility operates within a complex legal framework spanning the Controlled Substances Act, Securities Exchange Act, state cannabis regulations, and DEA registration requirements. The Controlled Substances Act of 1970, codified at 21 U.S.C. § 801 et seq., establishes the federal framework for controlled substance regulation. Section 812 creates five schedules of controlled substances based on abuse potential, accepted medical use, and safety profile. Cannabis remained in Schedule I from 1970 until May 2025, defined under 21 U.S.C. § 812(b)(1) as having high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. The DEA's March 2025 reclassification rule moved cannabis to Schedule III under 21 U.S.C. § 812(b)(3), which covers substances with moderate to low potential for physical dependence, currently accepted medical use, and abuse potential less than Schedule I or II substances. The reclassification did not legalize cannabis or remove it from CSA control—it changed the regulatory category and associated requirements. Schedule III substances require DEA registration for manufacturing, distribution, and dispensing under 21 U.S.C. § 823. The statute authorizes the Attorney General (acting through the DEA Administrator) to register applicants to manufacture or distribute controlled substances if registration is consistent with the public interest. Section 823(a) specifies six factors for evaluating public interest: maintenance of effective controls against diversion, compliance with state and local law, prior conviction record, past experience in controlled substance manufacturing or distribution, furnishing of false information, and other factors relevant to public health and safety. State cannabis laws create the operational framework for medical and adult-use programs. As of June 2026, 38 states and the District of Columbia have enacted medical cannabis laws, while 24 states and D.C. have legalized adult-use sales. State laws vary significantly in program structure, licensing requirements, possession limits, and qualifying medical conditions. Florida's medical cannabis program, established by Amendment 2 in 2016 and implemented through Florida Statutes § 381.986, authorizes licensed Medical Marijuana Treatment Centers to cultivate, process, and dispense cannabis to patients with qualifying conditions certified by licensed physicians. The state does not permit adult-use sales. Trulieve holds one of 22 MMTC licenses issued by Florida's Office of Medical Marijuana Use, operating 127 dispensaries serving approximately 520,000 registered patients as of March 2026. Pennsylvania's Medical Marijuana Act, 35 P.S. § 10231.101 et seq., established a medical-only program in 2016. The state issues separate grower/processor and dispensary permits, with 50 dispensary permits authorized statewide. Trulieve acquired three dispensary permits through its 2021 acquisition of PurePenn LLC, operating 23 dispensary locations. Pennsylvania does not permit adult-use sales, though legislative proposals to legalize recreational cannabis have been introduced in multiple sessions. The Securities Exchange Act of 1934, codified at 15 U.S.C. § 78a et seq., governs securities exchange registration, listing standards, and public company reporting requirements. Section 12(a) prohibits securities trading on national exchanges unless registered with the SEC. Section 12(b) authorizes exchanges to establish listing standards, subject to SEC approval, covering financial condition, corporate governance, and other criteria necessary to protect investors and the public interest. NYSE listing standards appear in the NYSE Listed Company Manual, requiring companies to meet minimum financial thresholds (typically $10 million in pre-tax income over the most recent three fiscal years and $100 million in aggregate), maintain specified corporate governance structures including independent director majorities and audit committees, and comply with applicable laws. The Manual's Section 102.01C specifies that the exchange will not list securities of a company that is not in compliance with applicable laws, rules, and regulations. The NYSE's May 2025 policy clarification interpreted the legal compliance requirement to permit listing of medical cannabis operators following Schedule III reclassification, reasoning that DEA-registered medical cannabis operations comply with federal law under the Controlled Substances Act. The policy explicitly excludes adult-use operations, which remain violations of 21 U.S.C. § 841 (prohibiting knowing or intentional manufacture, distribution, or dispensing of controlled substances except as authorized by the CSA). Tax treatment under Internal Revenue Code § 280E remains unchanged by reclassification. Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, but the prohibition does not extend to Schedule III substances. Cannabis operators may now deduct rent, salaries, marketing, and other ordinary expenses, eliminating the effective tax rates of 70 to 90 percent that characterized the industry under Schedule I. The change improves operator profitability but does not resolve banking access limitations or federal-state legal conflicts.

State-by-State Breakdown

Trulieve's restructuring required regulatory approval in nine states where the company holds licenses, with each state applying distinct standards for evaluating license transfers and corporate reorganizations.

Florida

Florida operates a medical-only cannabis program under Florida Statutes § 381.986, with no adult-use sales permitted. Trulieve holds a vertically integrated Medical Marijuana Treatment Center license authorizing cultivation, processing, and retail operations statewide. The company operates 127 dispensaries in Florida, representing approximately 59 percent of its total retail footprint. The Office of Medical Marijuana Use approved Trulieve's restructuring on November 8, 2025, determining that the corporate reorganization did not constitute a material change in ownership or control requiring new license application. The approval allowed Trulieve to maintain its MMTC license in the parent company pursuing NYSE listing, as Florida law does not authorize adult-use sales that would require separation. Florida's medical program serves approximately 890,000 registered patients as of May 2026, with qualifying conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, multiple sclerosis, and other debilitating conditions determined by licensed physicians. Patients may possess up to a 70-day supply of cannabis as determined by their certifying physician, with no specified possession limit.

Pennsylvania

Pennsylvania's Medical Marijuana Act, 35 P.S. § 10231.101 et seq., established a medical-only program with separate grower/processor and dispensary permits. Trulieve holds three dispensary permits, operating 23 locations across the state. The company does not hold grower/processor permits in Pennsylvania, sourcing products from licensed wholesale suppliers. The Pennsylvania Department of Health approved Trulieve's restructuring on December 3, 2025, after a 30-day review of the corporate reorganization plan. The approval was straightforward because Pennsylvania law does not authorize adult-use sales, eliminating the need to transfer licenses between entities. Pennsylvania's medical program serves approximately 470,000 registered patients as of April 2026. Qualifying conditions include cancer, epilepsy, HIV/AIDS, ALS, PTSD, Crohn's disease, Parkinson's disease, multiple sclerosis, severe chronic pain, intractable seizures, glaucoma, autism, and neurodegenerative diseases. Patients may possess up to a 90-day supply as determined by their certifying physician.

Massachusetts

Massachusetts operates a dual medical-adult-use system under Chapter 94G of the Massachusetts General Laws and 935 CMR 500.000 (adult-use regulations). Trulieve holds both medical and adult-use retail licenses, operating 18 dispensaries serving both patient and recreational markets. The Cannabis Control Commission approved Trulieve's restructuring on January 17, 2026, after a 60-day review process. The approval required Trulieve to transfer nine adult-use retail licenses to the newly formed Trulieve Adult Use LLC subsidiary, while maintaining nine medical-only licenses in the parent company. The CCC required the subsidiary to maintain separate management, comply with all adult-use regulations, and file quarterly reports on operational separation. Massachusetts' medical program serves approximately 78,000 registered patients as of March 2026, while adult-use sales reached $1.8 billion in 2025. Medical patients may possess up to a 60-day supply (10 ounces) of cannabis, while adult-use consumers may possess up to one ounce in public and up to 10 ounces at home.

Arizona

Arizona's Smart and Safe Act, approved by voters in November 2020 and codified in Arizona Revised Statutes § 36-2850 et seq., established adult-use legalization alongside the existing medical program. Trulieve operates 12 dispensaries in Arizona serving both medical patients and adult-use consumers. The Arizona Department of Health Services approved Trulieve's restructuring on January 29, 2026. The approval required transfer of seven dual-license dispensaries to the adult-use subsidiary, while five medical-only locations remained in the parent company. Arizona's regulatory framework permits single locations to serve both medical and adult-use customers through separate transaction systems, complicating the separation process. Arizona's medical program serves approximately 128,000 registered patients as of February 2026. Qualifying conditions include cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, Crohn's disease, Alzheimer's disease, cachexia, severe pain, severe nausea, seizures, muscle spasms, and PTSD. Medical patients may possess up to 2.5 ounces of cannabis every two weeks, while adult-use consumers may possess up to one ounce.

Ohio

Ohio operates a medical-only program under Ohio Revised Code § 3796, with adult-use legalization approved by voters in November 2023 but not yet implemented as of June 2026. Trulieve operates 14 medical dispensaries in Ohio through its Harvest Health & Recreation subsidiary acquired in 2021. The Ohio Division of Cannabis Control approved Trulieve's restructuring on February 12, 2026. Because Ohio had not yet implemented adult-use sales, the approval was administrative, confirming that the corporate reorganization did not affect medical dispensary licenses or operations. Ohio's medical program serves approximately 235,000 registered patients as of March 2026. Qualifying conditions include AIDS, ALS, Alzheimer's disease, cancer, chronic pain, Crohn's disease, epilepsy, fibromyalgia, glaucoma, hepatitis C, IBD, multiple sclerosis, Parkinson's disease, PTSD, sickle cell anemia, spinal cord injury, Tourette syndrome, traumatic brain injury, and ulcerative colitis. Patients may possess up to a 90-day supply as determined by their recommending physician, calculated based on dosage and form.

West Virginia

West Virginia's Medical Cannabis Act, West Virginia Code § 16A-1-1 et seq., established a medical-only program implemented in 2019. Trulieve operates eight dispensaries in West Virginia, with no adult-use program authorized under state law. The West Virginia Office of Medical Cannabis approved Trulieve's restructuring on February 24, 2026. The straightforward approval reflected the absence of adult-use operations requiring separation. West Virginia's medical program serves approximately 18,000 registered patients as of January 2026. Qualifying conditions include cancer, HIV/AIDS, ALS, Parkinson's disease, multiple sclerosis, spinal cord injury, epilepsy, neuropathy, Huntington's disease, Crohn's disease, PTSD, intractable seizures, sickle cell anemia, severe chronic pain, and terminal illness. Patients may possess up to a 30-day supply as determined by their certifying physician.

Maryland

Maryland operates a dual medical-adult-use system following voter approval of Question 4 in November 2022, with adult-use sales beginning July 1, 2023. Trulieve operates six dispensaries in Maryland serving both medical patients and recreational consumers. The Maryland Cannabis Administration approved Trulieve's restructuring on April 22, 2026, after the most extensive review process of any state. The MCA required detailed operational separation plans, financial projections for both entities, and commitments to maintain medical patient access and pricing. The approval required transfer of four dual-license locations to the adult-use subsidiary, while two medical-only dispensaries remained in the parent company. Maryland's medical program serves approximately 142,000 registered patients as of March 2026. Qualifying conditions include cachexia, anorexia, wasting syndrome, severe pain, severe nausea, seizures, severe muscle spasms, glaucoma, PTSD, and any other condition that is severe and resistant to conventional treatment. Medical patients may possess up to a 120-day supply (up to 36 ounces) of cannabis, while adult-use consumers may possess up to 1.5 ounces.

Market and Business Implications

NYSE listing eligibility creates a fundamental restructuring of U.S. cannabis capital markets, with implications spanning operator valuation, M&A strategy, institutional investment flows, and competitive dynamics between medical-only and integrated operators. Trulieve's restructuring separated approximately $890 million in annual adult-use revenue into a non-listed subsidiary, preserving roughly $1.2 billion in medical sales within the NYSE-listed parent company. The separation reduces consolidated revenue by 43 percent while maintaining 57 percent of sales in the exchange-listed entity. Securities analysts estimate the restructuring will increase Trulieve's enterprise value by 35 to 50 percent through multiple expansion, despite the revenue reduction. The valuation impact stems from institutional capital access. OTC-traded cannabis operators typically trade at enterprise value-to-revenue multiples of 1.5x to 2.5x, reflecting illiquidity discounts, regulatory risk, and institutional exclusion. Comparable healthcare and consumer packaged goods companies on major exchanges trade at 3.5x to 6.0x revenue multiples. If Trulieve achieves even the low end of this range, the company's enterprise value would increase from approximately $2.1 billion pre-restructuring to $4.2 billion post-listing, a $2.1 billion gain exceeding the $890 million in divested adult-use revenue. The restructuring model creates strategic optionality through the subsidiary structure. Trulieve Adult Use LLC remains wholly owned by existing shareholders through a tracking structure that distributes subsidiary shares proportionally. The subsidiary can pursue its own capital raising through private placements, debt financing, or eventual public listing if federal adult-use legalization occurs. This structure preserves adult-use upside for shareholders while capturing immediate NYSE listing benefits. At least seven other multi-state operators are pursuing similar restructuring strategies, according to securities filings and industry sources. Curaleaf Holdings announced in April 2026 that it had engaged advisors to evaluate medical-only restructuring for potential NYSE listing. Green Thumb Industries disclosed in May 2026 that its board had authorized management to explore strategic alternatives including corporate reorganization. Cresco Labs, Columbia Care, Verano Holdings, Ayr Wellness, and Ascend Wellness Holdings have all disclosed strategic reviews or restructuring evaluations in recent months. The restructuring wave creates a bifurcated industry structure with profound competitive implications. Medical-only operators accessing NYSE listing will secure institutional capital at lower costs, funding expansion, technology investment, and M&A activity. Adult-use-focused operators remaining on OTC markets will face persistent capital constraints, limiting growth and creating potential acquisition targets for better-capitalized medical operators. Wholesale pricing dynamics may shift as medical-only operators invest in cultivation efficiency and processing technology. Institutional capital access enables investment in automation, genetics research, and extraction technology that can reduce per-unit production costs. Medical operators may leverage these efficiencies to offer more competitive wholesale pricing to adult-use retailers, capturing margin in the supply chain while

Update — June 5, 2026: Trulieve becomes first plant-touching operator to list on NYSE

Trulieve Cannabis Corp. completed its transfer to the New York Stock Exchange on June 5, 2026, becoming the first U.S. multi-state operator with direct cannabis cultivation and retail operations to achieve a primary listing on the exchange. The Florida-based company began trading under ticker symbol TCNNF, migrating from its previous OTC Markets listing where it traded under the same symbol since 2018.

The listing followed the NYSE's March 2026 rule change approved by the Securities and Exchange Commission, which eliminated the prohibition on listing companies engaged in federally illegal activities provided they comply with state cannabis laws and meet enhanced disclosure requirements. Trulieve reported $1.3 billion in revenue for fiscal year 2025 and operates 195 dispensaries across 11 states, according to the company's most recent quarterly filing.

NYSE President Lynn Martin said the exchange worked with Trulieve for 14 months on compliance protocols specific to cannabis operators, including quarterly attestations of state regulatory standing and independent audits of supply chain controls. The listing requires Trulieve to maintain minimum market capitalization of $250 million and average daily trading volume above 100,000 shares, thresholds 25% higher than standard NYSE requirements.

The development marks a structural shift for cannabis capital markets, as institutional investors with NYSE-only mandates can now access plant-touching operators without OTC exposure. Trulieve's transfer opens the door for competitors including Curaleaf Holdings, Green Thumb Industries, and Verano Holdings, all of which have indicated intent to pursue NYSE listings pending final regulatory clarity on banking safe harbor provisions under the SAFER Banking Act.

Trulieve shares closed at $18.42 on June 5, up 7.3% from the prior OTC close, on volume of 4.2 million shares—nearly triple the 90-day average. The company's market capitalization stood at approximately $3.1 billion, making it the fourth-largest U.S. cannabis operator by valuation and the only one with direct access to NYSE's institutional investor base and index inclusion eligibility.

Update — June 8, 2026: First U.S. Cannabis Operator Lists on NYSE by Divesting Adult-Use Assets

A U.S. cannabis company achieved the first NYSE listing by a plant-touching operator by divesting its recreational cannabis operations and retaining only medical marijuana assets, according to High Times Magazine. The unnamed operator restructured its business model to comply with federal securities regulations, which prohibit exchanges from listing companies that violate the Controlled Substances Act. Medical cannabis programs operating under state law with stricter regulatory frameworks provided the compliance pathway that adult-use operations could not.

The listing represents a strategic pivot that prioritizes access to U.S. capital markets over participation in the larger recreational segment, which generated $29.7 billion in sales across 24 states in 2025. The operator's decision to exit adult-use markets eliminates revenue from the fastest-growing cannabis category but removes the federal illegality barrier that has confined plant-touching companies to the Canadian Securities Exchange and over-the-counter markets since 2018. NYSE listing requirements include compliance with all applicable laws, a standard that recreational cannabis operations cannot meet under current federal scheduling.

The restructuring required complete divestiture or spin-off of adult-use cultivation, processing, and retail assets before NYSE approval, according to the report. Medical-only operations serve approximately 2.8 million registered patients across 38 states, a market valued at $8.4 billion in 2025 but growing at only 4% annually compared to 12% growth in adult-use sales. The company's access to institutional investors, index fund inclusion, and lower cost of capital through NYSE listing may offset the revenue sacrifice from exiting recreational markets.

This listing establishes a replicable template for multi-state operators seeking major exchange access without waiting for federal rescheduling or the SAFE Banking Act. Competitors operating in both medical and adult-use segments now face a strategic decision: maintain diversified revenue streams on junior exchanges or pursue NYSE listing by narrowing to medical-only operations. The precedent confirms that federal compliance, not state-legal status, remains the determinative factor for major U.S. exchange eligibility in the cannabis sector.

Update — June 14, 2026: First U.S. Plant-Touching Cannabis Operator Lists on NYSE

A U.S. cannabis operator with direct plant-touching operations began trading on the New York Stock Exchange in June 2026, marking the first time a domestic marijuana company achieved a primary NYSE listing under federal Schedule III rescheduling rules. The listing followed the Drug Enforcement Administration's finalization of marijuana's rescheduling from Schedule I to Schedule III in early 2026, which removed the primary federal barrier that had previously confined U.S. cannabis operators to over-the-counter markets and Canadian exchanges. NYSE officials confirmed the company met all standard listing requirements, including minimum market capitalization thresholds and corporate governance standards, without requiring exemptions or waivers previously unavailable to cannabis issuers.

The milestone represents a structural shift in capital access for the U.S. cannabis sector. Plant-touching operators historically traded on the Canadian Securities Exchange or OTC Markets due to NYSE and Nasdaq policies that barred companies violating federal law, even when compliant with state regulations. Schedule III rescheduling eliminated that federal conflict for operators adhering to state-licensed frameworks, though companies remain subject to Internal Revenue Code Section 280E tax restrictions until Congress enacts separate legislative relief. Investment banks that previously declined to underwrite cannabis equity offerings have begun initiating coverage, with at least three bulge-bracket firms publishing research reports on newly exchange-eligible operators in the weeks following the listing.

The listing's immediate impact includes expanded institutional investor eligibility and enhanced liquidity for retail shareholders. Index inclusion becomes possible for the first time, as major providers including S&P Dow Jones Indices and FTSE Russell historically excluded companies engaged in federally illegal activities. Compliance departments at pension funds and mutual fund complexes that maintained blanket prohibitions on cannabis exposure have begun reviewing policies, according to industry legal counsel. Average daily trading volume for the newly listed operator exceeded over-the-counter volume by a factor of twelve in the first week, reflecting both institutional participation and tighter bid-ask spreads characteristic of major exchange trading.

Analysts expect additional U.S. multi-state operators to pursue NYSE or Nasdaq listings throughout 2026 and 2027. Companies must still demonstrate profitability or meet alternative financial standards, a threshold that excludes many smaller operators carrying accumulated deficits from years of restricted capital access and 280E tax burdens. The development does not affect ancillary cannabis service providers—including real estate investment trusts, hydroponics suppliers, and software vendors—that already traded on major exchanges prior to rescheduling, as those firms never directly handled federally controlled substances.

Update — June 17, 2026: Trulieve Becomes First U.S. Plant-Touching Operator Listed on NYSE

Trulieve Cannabis Corp. completed its transfer to the New York Stock Exchange on June 17, 2026, becoming the first U.S. multi-state operator with direct cannabis cultivation and retail operations to achieve a Big Board listing. The company began trading under the ticker symbol TCNNF, migrating from its previous over-the-counter quotation. According to the exchange filing, Trulieve met the NYSE's quantitative thresholds including minimum market capitalization of $100 million and pre-tax income requirements following the implementation of federal cannabis banking reforms in early 2026.

The listing followed the passage of the SAFER Banking Act in February 2026, which removed federal prohibitions on financial institutions serving state-licensed cannabis businesses. NYSE updated its listing standards in April 2026 to permit companies engaged in cannabis operations compliant with state law, ending a decade-long exclusion of plant-touching operators from major U.S. exchanges. Trulieve operated 193 retail dispensaries across 11 states at the time of listing, with reported annual revenue of $1.34 billion for fiscal year 2025.

Chief Executive Officer Kim Rivers said the NYSE listing "provides institutional investors access to the cannabis sector through a regulated exchange for the first time." The company's transfer application, filed May 3, 2026, documented compliance with Financial Industry Regulatory Authority Rule 6490 and satisfaction of the exchange's corporate governance standards. Trading volume on the first day reached 47.2 million shares, with the stock closing at $18.75, representing a market capitalization of approximately $3.8 billion.

The milestone opened NYSE access to other multi-state operators including Curaleaf Holdings, Green Thumb Industries, and Verano Holdings, all of which filed preliminary listing applications within 72 hours of Trulieve's debut. For institutional investors previously restricted by compliance policies prohibiting OTC securities, the NYSE listing created eligibility for index inclusion and removed barriers that had confined an estimated $28 billion in U.S. cannabis equity value to fragmented quotation systems since 2014.

Trulieve's banking relationships expanded immediately following the listing, with JPMorgan Chase and Bank of America establishing credit facilities totaling $450 million according to securities filings dated June 18, 2026. The access to traditional banking and capital markets infrastructure addressed operational constraints that had forced cannabis operators to rely on cash management and alternative lenders charging interest rates exceeding 15 percent annually.